Project in brief
This PhD project will evaluate whether antiretroviral medications used for HIV can prevent development of cervical cancer.
In November 2023 the NHS pledged to eliminate cervical cancer by 2040. Targeting the Human Papillomavirus (HPV) that causes 99% of cervical cancers is essential if this eradication target is to be achieved. HPV-mediated inflammation is key to its role in causing cervical cancer with the activation of the nuclear transcription factor NF-kB playing a central role.
We have recently identified antiretroviral medications used clinically for both the treatment of and pre-exposure prophylaxis against HIV infection that also inhibit NF-kB activation. This project aims to investigate the ability of the antiretroviral drugs to reduce viral-induced inflammation in human cervical cancer cells and identify the cellular molecular pathways involved. It is envisaged that the study will provide preclinical data supporting the use of these drugs in HPV infection.
This project will deliver training in a suite of valuable, highly transferable laboratory skills including both cellular and molecular biology techniques, that will prepare you for a wide variety of career options.
Key Facts
Location Moulsecoomb campus, Brighton
Research centre Centre for Lifelong Health
Project themes Cervical cancer, antiretroviral drugs, inflammation, medicines optimization
Deadline Thursday 29 February 2024 at 16.00 GMT
Interviews March 2024